# Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

> **NCT02824952** · PHASE2 · UNKNOWN · sponsor: **Shaare Zedek Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Lung Cancer, Non-small Cell

## Interventions

- **DRUG:** Tagrisso

## Key facts

- **NCT ID:** NCT02824952
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02824952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02824952, "Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02824952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*